Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Beyond BCR::ABL1—The Role of Genomic Analyses in the Management of CML

1 Feb 2024

Abstract excerpt

Chronic myeloid leukemia (CML) is a model of genomically based diagnosis and management where BCR::ABL1 is successfully targeted by tyrosine kinase inhibitor (TKI) therapy in most patients. The dynamics of BCR::ABL1 transcript decline during therapy is a dependable biomarker of response, relapse, and drug resistance. Missense mutations acquired within the BCR::ABL1 kinase domain that disrupt TKI binding can...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Fungal Plant Pathogen Control

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38394774
DOI: 10.6004/jnccn.2023.7335

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Beyond BCR::ABL1—The Role of Genomic Analyses in the Management of CMLPMID 38394774Read ↗

Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia.Semantic proximity Read ↗

Molecular monitoring of chronic myeloid leukemia: present and future.Semantic proximity Read ↗

The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?Semantic proximity Read ↗

Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression.Semantic proximity Read ↗

Molecular biology of bcr-abl1–positive chronic myeloid leukemiaSemantic proximity Read ↗

Molecular monitoring in CML: how deep? How often? How should it influence therapy?Semantic proximity Read ↗

Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid Leukemia.Semantic proximity Read ↗

How will genomic testing impact a clinician's choice for managing chronic myeloid leukemia?Semantic proximity Read ↗

Genetic landscape of chronic myeloid leukemia.Semantic proximity Read ↗

Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.Semantic proximity Read ↗

Chronic Myeloid Leukemia: Beyond BCR-ABL1Semantic proximity Read ↗

Clinical Applications of BCR-ABL Molecular Testing in Acute LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.